nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—DRD3—Bromocriptine—type 2 diabetes mellitus	0.171	0.38	CbGbCtD
Metoclopramide—DRD2—Bromocriptine—type 2 diabetes mellitus	0.1	0.222	CbGbCtD
Metoclopramide—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.0527	0.117	CbGbCtD
Metoclopramide—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.0486	0.108	CbGbCtD
Metoclopramide—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.0399	0.0885	CbGbCtD
Metoclopramide—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.0383	0.0849	CbGbCtD
Metoclopramide—Sunitinib—INSR—type 2 diabetes mellitus	0.00265	0.293	CrCbGaD
Metoclopramide—Sunitinib—PRKAA1—type 2 diabetes mellitus	0.00179	0.198	CrCbGaD
Metoclopramide—Cinchocaine—CALM1—type 2 diabetes mellitus	0.00161	0.178	CrCbGaD
Metoclopramide—Procainamide—DNMT1—type 2 diabetes mellitus	0.00106	0.117	CrCbGaD
Metoclopramide—Cisapride—HTR2C—type 2 diabetes mellitus	0.000598	0.0662	CrCbGaD
Metoclopramide—Cisapride—CYP1A2—type 2 diabetes mellitus	0.000451	0.0499	CrCbGaD
Metoclopramide—Tremor—Gliclazide—type 2 diabetes mellitus	0.000447	0.00163	CcSEcCtD
Metoclopramide—Feeling abnormal—Pioglitazone—type 2 diabetes mellitus	0.000445	0.00163	CcSEcCtD
Metoclopramide—Hypotension—Bromocriptine—type 2 diabetes mellitus	0.000444	0.00162	CcSEcCtD
Metoclopramide—Jaundice—Losartan—type 2 diabetes mellitus	0.000443	0.00162	CcSEcCtD
Metoclopramide—Bradycardia—Irbesartan—type 2 diabetes mellitus	0.000441	0.00161	CcSEcCtD
Metoclopramide—Diarrhoea—Rosiglitazone—type 2 diabetes mellitus	0.000441	0.00161	CcSEcCtD
Metoclopramide—Agitation—Gliclazide—type 2 diabetes mellitus	0.000439	0.0016	CcSEcCtD
Metoclopramide—Confusional state—Glyburide—type 2 diabetes mellitus	0.000438	0.0016	CcSEcCtD
Metoclopramide—Asthma—Ramipril—type 2 diabetes mellitus	0.000437	0.00159	CcSEcCtD
Metoclopramide—Angioedema—Gliclazide—type 2 diabetes mellitus	0.000436	0.00159	CcSEcCtD
Metoclopramide—Oedema—Glyburide—type 2 diabetes mellitus	0.000434	0.00158	CcSEcCtD
Metoclopramide—Feeling abnormal—Glimepiride—type 2 diabetes mellitus	0.000434	0.00158	CcSEcCtD
Metoclopramide—Feeling abnormal—Sitagliptin—type 2 diabetes mellitus	0.000432	0.00158	CcSEcCtD
Metoclopramide—Rash—Repaglinide—type 2 diabetes mellitus	0.00043	0.00157	CcSEcCtD
Metoclopramide—Bronchospasm—Ramipril—type 2 diabetes mellitus	0.000429	0.00157	CcSEcCtD
Metoclopramide—Insomnia—Bromocriptine—type 2 diabetes mellitus	0.000429	0.00157	CcSEcCtD
Metoclopramide—Dermatitis—Repaglinide—type 2 diabetes mellitus	0.000429	0.00157	CcSEcCtD
Metoclopramide—Urticaria—Pioglitazone—type 2 diabetes mellitus	0.000429	0.00157	CcSEcCtD
Metoclopramide—Leukopenia—Gliclazide—type 2 diabetes mellitus	0.000427	0.00156	CcSEcCtD
Metoclopramide—Headache—Repaglinide—type 2 diabetes mellitus	0.000427	0.00156	CcSEcCtD
Metoclopramide—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.000426	0.00156	CcSEcCtD
Metoclopramide—Flushing—Metformin—type 2 diabetes mellitus	0.000426	0.00156	CcSEcCtD
Metoclopramide—Agranulocytosis—Losartan—type 2 diabetes mellitus	0.000424	0.00155	CcSEcCtD
Metoclopramide—Dyspnoea—Bromocriptine—type 2 diabetes mellitus	0.000423	0.00155	CcSEcCtD
Metoclopramide—Somnolence—Bromocriptine—type 2 diabetes mellitus	0.000422	0.00154	CcSEcCtD
Metoclopramide—Palpitations—Gliclazide—type 2 diabetes mellitus	0.000422	0.00154	CcSEcCtD
Metoclopramide—Muscle spasms—Valsartan—type 2 diabetes mellitus	0.000422	0.00154	CcSEcCtD
Metoclopramide—Urticaria—Glimepiride—type 2 diabetes mellitus	0.000418	0.00153	CcSEcCtD
Metoclopramide—Visual impairment—Irbesartan—type 2 diabetes mellitus	0.000417	0.00152	CcSEcCtD
Metoclopramide—Muscle spasms—Orlistat—type 2 diabetes mellitus	0.000417	0.00152	CcSEcCtD
Metoclopramide—Urticaria—Sitagliptin—type 2 diabetes mellitus	0.000417	0.00152	CcSEcCtD
Metoclopramide—Hypersensitivity—Glipizide—type 2 diabetes mellitus	0.000415	0.00152	CcSEcCtD
Metoclopramide—Convulsion—Gliclazide—type 2 diabetes mellitus	0.000414	0.00151	CcSEcCtD
Metoclopramide—Hypertension—Gliclazide—type 2 diabetes mellitus	0.000412	0.00151	CcSEcCtD
Metoclopramide—Fatigue—Bromocriptine—type 2 diabetes mellitus	0.000409	0.00149	CcSEcCtD
Metoclopramide—Neutropenia—Ramipril—type 2 diabetes mellitus	0.000408	0.00149	CcSEcCtD
Metoclopramide—Rash—Rosiglitazone—type 2 diabetes mellitus	0.000406	0.00148	CcSEcCtD
Metoclopramide—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	0.000406	0.00148	CcSEcCtD
Metoclopramide—Hypotension—Glyburide—type 2 diabetes mellitus	0.000406	0.00148	CcSEcCtD
Metoclopramide—Anxiety—Gliclazide—type 2 diabetes mellitus	0.000405	0.00148	CcSEcCtD
Metoclopramide—Nausea—Repaglinide—type 2 diabetes mellitus	0.000405	0.00148	CcSEcCtD
Metoclopramide—Asthenia—Glipizide—type 2 diabetes mellitus	0.000405	0.00148	CcSEcCtD
Metoclopramide—Headache—Rosiglitazone—type 2 diabetes mellitus	0.000404	0.00147	CcSEcCtD
Metoclopramide—Erectile dysfunction—Ramipril—type 2 diabetes mellitus	0.000402	0.00147	CcSEcCtD
Metoclopramide—Flushing—Irbesartan—type 2 diabetes mellitus	0.000402	0.00147	CcSEcCtD
Metoclopramide—Sunitinib—ABCC2—type 2 diabetes mellitus	0.000402	0.0445	CrCbGaD
Metoclopramide—Angioedema—Valsartan—type 2 diabetes mellitus	0.000401	0.00146	CcSEcCtD
Metoclopramide—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	0.000398	0.00145	CcSEcCtD
Metoclopramide—Angioedema—Orlistat—type 2 diabetes mellitus	0.000396	0.00145	CcSEcCtD
Metoclopramide—Confusional state—Gliclazide—type 2 diabetes mellitus	0.000393	0.00143	CcSEcCtD
Metoclopramide—Feeling abnormal—Bromocriptine—type 2 diabetes mellitus	0.000391	0.00143	CcSEcCtD
Metoclopramide—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	0.000388	0.00142	CcSEcCtD
Metoclopramide—Palpitations—Valsartan—type 2 diabetes mellitus	0.000388	0.00142	CcSEcCtD
Metoclopramide—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.000388	0.00142	CcSEcCtD
Metoclopramide—Dyspnoea—Glyburide—type 2 diabetes mellitus	0.000387	0.00141	CcSEcCtD
Metoclopramide—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.000386	0.00141	CcSEcCtD
Metoclopramide—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.000386	0.00141	CcSEcCtD
Metoclopramide—Muscle spasms—Metformin—type 2 diabetes mellitus	0.000384	0.0014	CcSEcCtD
Metoclopramide—Palpitations—Orlistat—type 2 diabetes mellitus	0.000383	0.0014	CcSEcCtD
Metoclopramide—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000383	0.0014	CcSEcCtD
Metoclopramide—Tachycardia—Gliclazide—type 2 diabetes mellitus	0.00038	0.00139	CcSEcCtD
Metoclopramide—Jaundice—Ramipril—type 2 diabetes mellitus	0.000379	0.00139	CcSEcCtD
Metoclopramide—Flushing—Losartan—type 2 diabetes mellitus	0.000378	0.00138	CcSEcCtD
Metoclopramide—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000378	0.00138	CcSEcCtD
Metoclopramide—Urticaria—Bromocriptine—type 2 diabetes mellitus	0.000377	0.00138	CcSEcCtD
Metoclopramide—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000376	0.00137	CcSEcCtD
Metoclopramide—Convulsion—Orlistat—type 2 diabetes mellitus	0.000376	0.00137	CcSEcCtD
Metoclopramide—Body temperature increased—Bromocriptine—type 2 diabetes mellitus	0.000375	0.00137	CcSEcCtD
Metoclopramide—Tremor—Metformin—type 2 diabetes mellitus	0.000374	0.00137	CcSEcCtD
Metoclopramide—Dizziness—Glipizide—type 2 diabetes mellitus	0.000373	0.00136	CcSEcCtD
Metoclopramide—Anxiety—Valsartan—type 2 diabetes mellitus	0.000372	0.00136	CcSEcCtD
Metoclopramide—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.00037	0.00135	CcSEcCtD
Metoclopramide—Anxiety—Orlistat—type 2 diabetes mellitus	0.000368	0.00134	CcSEcCtD
Metoclopramide—Nervousness—Irbesartan—type 2 diabetes mellitus	0.000366	0.00134	CcSEcCtD
Metoclopramide—Hypotension—Gliclazide—type 2 diabetes mellitus	0.000364	0.00133	CcSEcCtD
Metoclopramide—Agranulocytosis—Ramipril—type 2 diabetes mellitus	0.000363	0.00133	CcSEcCtD
Metoclopramide—Muscle spasms—Irbesartan—type 2 diabetes mellitus	0.000362	0.00132	CcSEcCtD
Metoclopramide—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.00036	0.00131	CcSEcCtD
Metoclopramide—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.000359	0.00131	CcSEcCtD
Metoclopramide—Oedema—Valsartan—type 2 diabetes mellitus	0.000358	0.00131	CcSEcCtD
Metoclopramide—Feeling abnormal—Glyburide—type 2 diabetes mellitus	0.000358	0.00131	CcSEcCtD
Metoclopramide—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000357	0.0013	CcSEcCtD
Metoclopramide—Rash—Glipizide—type 2 diabetes mellitus	0.000356	0.0013	CcSEcCtD
Metoclopramide—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000355	0.0013	CcSEcCtD
Metoclopramide—Oedema—Orlistat—type 2 diabetes mellitus	0.000354	0.00129	CcSEcCtD
Metoclopramide—Headache—Glipizide—type 2 diabetes mellitus	0.000353	0.00129	CcSEcCtD
Metoclopramide—Tremor—Irbesartan—type 2 diabetes mellitus	0.000353	0.00129	CcSEcCtD
Metoclopramide—Palpitations—Metformin—type 2 diabetes mellitus	0.000353	0.00129	CcSEcCtD
Metoclopramide—Insomnia—Gliclazide—type 2 diabetes mellitus	0.000352	0.00129	CcSEcCtD
Metoclopramide—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000348	0.00127	CcSEcCtD
Metoclopramide—Dyspnoea—Gliclazide—type 2 diabetes mellitus	0.000347	0.00127	CcSEcCtD
Metoclopramide—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000347	0.00127	CcSEcCtD
Metoclopramide—Agitation—Irbesartan—type 2 diabetes mellitus	0.000346	0.00127	CcSEcCtD
Metoclopramide—Somnolence—Gliclazide—type 2 diabetes mellitus	0.000346	0.00127	CcSEcCtD
Metoclopramide—Hypertension—Metformin—type 2 diabetes mellitus	0.000345	0.00126	CcSEcCtD
Metoclopramide—Urticaria—Glyburide—type 2 diabetes mellitus	0.000345	0.00126	CcSEcCtD
Metoclopramide—Nervousness—Losartan—type 2 diabetes mellitus	0.000345	0.00126	CcSEcCtD
Metoclopramide—Angioedema—Irbesartan—type 2 diabetes mellitus	0.000344	0.00126	CcSEcCtD
Metoclopramide—Muscle spasms—Losartan—type 2 diabetes mellitus	0.000341	0.00125	CcSEcCtD
Metoclopramide—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000341	0.00124	CcSEcCtD
Metoclopramide—Headache—Pioglitazone—type 2 diabetes mellitus	0.000338	0.00124	CcSEcCtD
Metoclopramide—Leukopenia—Irbesartan—type 2 diabetes mellitus	0.000337	0.00123	CcSEcCtD
Metoclopramide—Visual impairment—Ramipril—type 2 diabetes mellitus	0.000337	0.00123	CcSEcCtD
Metoclopramide—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000336	0.00123	CcSEcCtD
Metoclopramide—Nausea—Glipizide—type 2 diabetes mellitus	0.000335	0.00122	CcSEcCtD
Metoclopramide—Hypotension—Valsartan—type 2 diabetes mellitus	0.000335	0.00122	CcSEcCtD
Metoclopramide—Tremor—Losartan—type 2 diabetes mellitus	0.000332	0.00121	CcSEcCtD
Metoclopramide—Rash—Glimepiride—type 2 diabetes mellitus	0.000332	0.00121	CcSEcCtD
Metoclopramide—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000331	0.00121	CcSEcCtD
Metoclopramide—Rash—Sitagliptin—type 2 diabetes mellitus	0.000331	0.00121	CcSEcCtD
Metoclopramide—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.00033	0.00121	CcSEcCtD
Metoclopramide—Headache—Glimepiride—type 2 diabetes mellitus	0.00033	0.0012	CcSEcCtD
Metoclopramide—Headache—Sitagliptin—type 2 diabetes mellitus	0.000329	0.0012	CcSEcCtD
Metoclopramide—Agitation—Losartan—type 2 diabetes mellitus	0.000326	0.00119	CcSEcCtD
Metoclopramide—Oedema—Metformin—type 2 diabetes mellitus	0.000326	0.00119	CcSEcCtD
Metoclopramide—Hypertension—Irbesartan—type 2 diabetes mellitus	0.000325	0.00119	CcSEcCtD
Metoclopramide—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000325	0.00119	CcSEcCtD
Metoclopramide—Flushing—Ramipril—type 2 diabetes mellitus	0.000324	0.00118	CcSEcCtD
Metoclopramide—Angioedema—Losartan—type 2 diabetes mellitus	0.000324	0.00118	CcSEcCtD
Metoclopramide—Insomnia—Valsartan—type 2 diabetes mellitus	0.000324	0.00118	CcSEcCtD
Metoclopramide—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.000321	0.00117	CcSEcCtD
Metoclopramide—Insomnia—Orlistat—type 2 diabetes mellitus	0.00032	0.00117	CcSEcCtD
Metoclopramide—Anxiety—Irbesartan—type 2 diabetes mellitus	0.00032	0.00117	CcSEcCtD
Metoclopramide—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.00032	0.00117	CcSEcCtD
Metoclopramide—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000319	0.00117	CcSEcCtD
Metoclopramide—Somnolence—Valsartan—type 2 diabetes mellitus	0.000318	0.00116	CcSEcCtD
Metoclopramide—Leukopenia—Losartan—type 2 diabetes mellitus	0.000318	0.00116	CcSEcCtD
Metoclopramide—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000314	0.00115	CcSEcCtD
Metoclopramide—Palpitations—Losartan—type 2 diabetes mellitus	0.000314	0.00114	CcSEcCtD
Metoclopramide—Nausea—Glimepiride—type 2 diabetes mellitus	0.000313	0.00114	CcSEcCtD
Metoclopramide—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000312	0.00114	CcSEcCtD
Metoclopramide—Asthenia—Glyburide—type 2 diabetes mellitus	0.000311	0.00114	CcSEcCtD
Metoclopramide—Urticaria—Gliclazide—type 2 diabetes mellitus	0.00031	0.00113	CcSEcCtD
Metoclopramide—Fatigue—Valsartan—type 2 diabetes mellitus	0.000309	0.00113	CcSEcCtD
Metoclopramide—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000308	0.00112	CcSEcCtD
Metoclopramide—Oedema—Irbesartan—type 2 diabetes mellitus	0.000308	0.00112	CcSEcCtD
Metoclopramide—Fatigue—Orlistat—type 2 diabetes mellitus	0.000305	0.00111	CcSEcCtD
Metoclopramide—Hypotension—Metformin—type 2 diabetes mellitus	0.000305	0.00111	CcSEcCtD
Metoclopramide—Anxiety—Losartan—type 2 diabetes mellitus	0.000301	0.0011	CcSEcCtD
Metoclopramide—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.0003	0.0011	CcSEcCtD
Metoclopramide—Rash—Bromocriptine—type 2 diabetes mellitus	0.000299	0.00109	CcSEcCtD
Metoclopramide—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000299	0.00109	CcSEcCtD
Metoclopramide—Cisapride—CYP3A4—type 2 diabetes mellitus	0.000299	0.033	CrCbGaD
Metoclopramide—Headache—Bromocriptine—type 2 diabetes mellitus	0.000297	0.00109	CcSEcCtD
Metoclopramide—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000297	0.00108	CcSEcCtD
Metoclopramide—Nervousness—Ramipril—type 2 diabetes mellitus	0.000295	0.00108	CcSEcCtD
Metoclopramide—Muscle spasms—Ramipril—type 2 diabetes mellitus	0.000292	0.00107	CcSEcCtD
Metoclopramide—Confusional state—Losartan—type 2 diabetes mellitus	0.000292	0.00107	CcSEcCtD
Metoclopramide—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.000292	0.00106	CcSEcCtD
Metoclopramide—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000291	0.00106	CcSEcCtD
Metoclopramide—Somnolence—Metformin—type 2 diabetes mellitus	0.00029	0.00106	CcSEcCtD
Metoclopramide—Oedema—Losartan—type 2 diabetes mellitus	0.00029	0.00106	CcSEcCtD
Metoclopramide—Hypotension—Irbesartan—type 2 diabetes mellitus	0.000288	0.00105	CcSEcCtD
Metoclopramide—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.000287	0.00105	CcSEcCtD
Metoclopramide—Tremor—Ramipril—type 2 diabetes mellitus	0.000285	0.00104	CcSEcCtD
Metoclopramide—Urticaria—Valsartan—type 2 diabetes mellitus	0.000284	0.00104	CcSEcCtD
Metoclopramide—Tachycardia—Losartan—type 2 diabetes mellitus	0.000283	0.00103	CcSEcCtD
Metoclopramide—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000282	0.00103	CcSEcCtD
Metoclopramide—Fatigue—Metformin—type 2 diabetes mellitus	0.000281	0.00103	CcSEcCtD
Metoclopramide—Urticaria—Orlistat—type 2 diabetes mellitus	0.000281	0.00103	CcSEcCtD
Metoclopramide—Body temperature increased—Orlistat—type 2 diabetes mellitus	0.00028	0.00102	CcSEcCtD
Metoclopramide—Asthenia—Gliclazide—type 2 diabetes mellitus	0.00028	0.00102	CcSEcCtD
Metoclopramide—Agitation—Ramipril—type 2 diabetes mellitus	0.00028	0.00102	CcSEcCtD
Metoclopramide—Angioedema—Ramipril—type 2 diabetes mellitus	0.000278	0.00102	CcSEcCtD
Metoclopramide—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.000274	0.001	CcSEcCtD
Metoclopramide—Rash—Glyburide—type 2 diabetes mellitus	0.000274	0.000999	CcSEcCtD
Metoclopramide—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000274	0.000999	CcSEcCtD
Metoclopramide—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000273	0.000998	CcSEcCtD
Metoclopramide—Leukopenia—Ramipril—type 2 diabetes mellitus	0.000272	0.000994	CcSEcCtD
Metoclopramide—Headache—Glyburide—type 2 diabetes mellitus	0.000272	0.000993	CcSEcCtD
Metoclopramide—Hypotension—Losartan—type 2 diabetes mellitus	0.000271	0.000988	CcSEcCtD
Metoclopramide—Palpitations—Ramipril—type 2 diabetes mellitus	0.000269	0.000982	CcSEcCtD
Metoclopramide—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.000269	0.000981	CcSEcCtD
Metoclopramide—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000267	0.000974	CcSEcCtD
Metoclopramide—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000265	0.000969	CcSEcCtD
Metoclopramide—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.000264	0.000963	CcSEcCtD
Metoclopramide—Convulsion—Ramipril—type 2 diabetes mellitus	0.000264	0.000963	CcSEcCtD
Metoclopramide—Insomnia—Losartan—type 2 diabetes mellitus	0.000262	0.000956	CcSEcCtD
Metoclopramide—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000261	0.000952	CcSEcCtD
Metoclopramide—Urticaria—Metformin—type 2 diabetes mellitus	0.000259	0.000946	CcSEcCtD
Metoclopramide—Dyspnoea—Losartan—type 2 diabetes mellitus	0.000258	0.000943	CcSEcCtD
Metoclopramide—Anxiety—Ramipril—type 2 diabetes mellitus	0.000258	0.000943	CcSEcCtD
Metoclopramide—Nausea—Glyburide—type 2 diabetes mellitus	0.000258	0.000941	CcSEcCtD
Metoclopramide—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000258	0.000941	CcSEcCtD
Metoclopramide—Somnolence—Losartan—type 2 diabetes mellitus	0.000257	0.00094	CcSEcCtD
Metoclopramide—Asthenia—Valsartan—type 2 diabetes mellitus	0.000257	0.000938	CcSEcCtD
Metoclopramide—Asthenia—Orlistat—type 2 diabetes mellitus	0.000254	0.000927	CcSEcCtD
Metoclopramide—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	0.000254	0.000926	CcSEcCtD
Metoclopramide—Confusional state—Ramipril—type 2 diabetes mellitus	0.00025	0.000914	CcSEcCtD
Metoclopramide—Fatigue—Losartan—type 2 diabetes mellitus	0.00025	0.000912	CcSEcCtD
Metoclopramide—Oedema—Ramipril—type 2 diabetes mellitus	0.000248	0.000907	CcSEcCtD
Metoclopramide—Rash—Gliclazide—type 2 diabetes mellitus	0.000246	0.000897	CcSEcCtD
Metoclopramide—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000245	0.000896	CcSEcCtD
Metoclopramide—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000245	0.000895	CcSEcCtD
Metoclopramide—Urticaria—Irbesartan—type 2 diabetes mellitus	0.000244	0.000893	CcSEcCtD
Metoclopramide—Headache—Gliclazide—type 2 diabetes mellitus	0.000244	0.000891	CcSEcCtD
Metoclopramide—Body temperature increased—Irbesartan—type 2 diabetes mellitus	0.000243	0.000888	CcSEcCtD
Metoclopramide—Tachycardia—Ramipril—type 2 diabetes mellitus	0.000242	0.000885	CcSEcCtD
Metoclopramide—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000242	0.000884	CcSEcCtD
Metoclopramide—Feeling abnormal—Losartan—type 2 diabetes mellitus	0.000239	0.000871	CcSEcCtD
Metoclopramide—Dizziness—Valsartan—type 2 diabetes mellitus	0.000237	0.000865	CcSEcCtD
Metoclopramide—Dizziness—Orlistat—type 2 diabetes mellitus	0.000234	0.000854	CcSEcCtD
Metoclopramide—Asthenia—Metformin—type 2 diabetes mellitus	0.000234	0.000854	CcSEcCtD
Metoclopramide—Hypotension—Ramipril—type 2 diabetes mellitus	0.000232	0.000847	CcSEcCtD
Metoclopramide—Nausea—Gliclazide—type 2 diabetes mellitus	0.000231	0.000845	CcSEcCtD
Metoclopramide—Urticaria—Losartan—type 2 diabetes mellitus	0.00023	0.00084	CcSEcCtD
Metoclopramide—Body temperature increased—Losartan—type 2 diabetes mellitus	0.000229	0.000836	CcSEcCtD
Metoclopramide—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.000227	0.000828	CcSEcCtD
Metoclopramide—Rash—Valsartan—type 2 diabetes mellitus	0.000226	0.000824	CcSEcCtD
Metoclopramide—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000226	0.000824	CcSEcCtD
Metoclopramide—Insomnia—Ramipril—type 2 diabetes mellitus	0.000225	0.00082	CcSEcCtD
Metoclopramide—Headache—Valsartan—type 2 diabetes mellitus	0.000224	0.000819	CcSEcCtD
Metoclopramide—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000223	0.000815	CcSEcCtD
Metoclopramide—Rash—Orlistat—type 2 diabetes mellitus	0.000223	0.000815	CcSEcCtD
Metoclopramide—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000223	0.000814	CcSEcCtD
Metoclopramide—Headache—Orlistat—type 2 diabetes mellitus	0.000222	0.000809	CcSEcCtD
Metoclopramide—Dyspnoea—Ramipril—type 2 diabetes mellitus	0.000221	0.000808	CcSEcCtD
Metoclopramide—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000221	0.000806	CcSEcCtD
Metoclopramide—Somnolence—Ramipril—type 2 diabetes mellitus	0.000221	0.000806	CcSEcCtD
Metoclopramide—Dizziness—Metformin—type 2 diabetes mellitus	0.000216	0.000787	CcSEcCtD
Metoclopramide—Fatigue—Ramipril—type 2 diabetes mellitus	0.000214	0.000782	CcSEcCtD
Metoclopramide—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.000213	0.000779	CcSEcCtD
Metoclopramide—Nausea—Valsartan—type 2 diabetes mellitus	0.000213	0.000777	CcSEcCtD
Metoclopramide—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000211	0.000769	CcSEcCtD
Metoclopramide—Nausea—Orlistat—type 2 diabetes mellitus	0.00021	0.000767	CcSEcCtD
Metoclopramide—Asthenia—Losartan—type 2 diabetes mellitus	0.000208	0.000759	CcSEcCtD
Metoclopramide—Rash—Metformin—type 2 diabetes mellitus	0.000206	0.000751	CcSEcCtD
Metoclopramide—Dermatitis—Metformin—type 2 diabetes mellitus	0.000205	0.00075	CcSEcCtD
Metoclopramide—Feeling abnormal—Ramipril—type 2 diabetes mellitus	0.000205	0.000747	CcSEcCtD
Metoclopramide—Headache—Metformin—type 2 diabetes mellitus	0.000204	0.000746	CcSEcCtD
Metoclopramide—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000203	0.000743	CcSEcCtD
Metoclopramide—Diarrhoea—Losartan—type 2 diabetes mellitus	0.000198	0.000723	CcSEcCtD
Metoclopramide—Urticaria—Ramipril—type 2 diabetes mellitus	0.000197	0.00072	CcSEcCtD
Metoclopramide—Body temperature increased—Ramipril—type 2 diabetes mellitus	0.000196	0.000717	CcSEcCtD
Metoclopramide—Rash—Irbesartan—type 2 diabetes mellitus	0.000194	0.000708	CcSEcCtD
Metoclopramide—Dermatitis—Irbesartan—type 2 diabetes mellitus	0.000194	0.000708	CcSEcCtD
Metoclopramide—Nausea—Metformin—type 2 diabetes mellitus	0.000194	0.000707	CcSEcCtD
Metoclopramide—Headache—Irbesartan—type 2 diabetes mellitus	0.000193	0.000704	CcSEcCtD
Metoclopramide—Dizziness—Losartan—type 2 diabetes mellitus	0.000191	0.000699	CcSEcCtD
Metoclopramide—Hypersensitivity—Ramipril—type 2 diabetes mellitus	0.000183	0.000668	CcSEcCtD
Metoclopramide—Nausea—Irbesartan—type 2 diabetes mellitus	0.000183	0.000667	CcSEcCtD
Metoclopramide—Rash—Losartan—type 2 diabetes mellitus	0.000183	0.000667	CcSEcCtD
Metoclopramide—Dermatitis—Losartan—type 2 diabetes mellitus	0.000182	0.000666	CcSEcCtD
Metoclopramide—Headache—Losartan—type 2 diabetes mellitus	0.000181	0.000662	CcSEcCtD
Metoclopramide—Asthenia—Ramipril—type 2 diabetes mellitus	0.000178	0.00065	CcSEcCtD
Metoclopramide—Sunitinib—CYP3A4—type 2 diabetes mellitus	0.000178	0.0197	CrCbGaD
Metoclopramide—Nausea—Losartan—type 2 diabetes mellitus	0.000172	0.000628	CcSEcCtD
Metoclopramide—Diarrhoea—Ramipril—type 2 diabetes mellitus	0.00017	0.00062	CcSEcCtD
Metoclopramide—Dizziness—Ramipril—type 2 diabetes mellitus	0.000164	0.0006	CcSEcCtD
Metoclopramide—Rash—Ramipril—type 2 diabetes mellitus	0.000157	0.000572	CcSEcCtD
Metoclopramide—Dermatitis—Ramipril—type 2 diabetes mellitus	0.000156	0.000571	CcSEcCtD
Metoclopramide—Headache—Ramipril—type 2 diabetes mellitus	0.000156	0.000568	CcSEcCtD
Metoclopramide—Nausea—Ramipril—type 2 diabetes mellitus	0.000147	0.000539	CcSEcCtD
Metoclopramide—DRD2—Signaling by GPCR—CCR5—type 2 diabetes mellitus	1.44e-05	5.41e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.44e-05	5.4e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TRPC6—type 2 diabetes mellitus	1.44e-05	5.39e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	1.43e-05	5.39e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AGTR2—type 2 diabetes mellitus	1.43e-05	5.36e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.41e-05	5.31e-05	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.41e-05	5.3e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CCR5—type 2 diabetes mellitus	1.41e-05	5.29e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—C3—type 2 diabetes mellitus	1.41e-05	5.28e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EDNRB—type 2 diabetes mellitus	1.4e-05	5.25e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—C3—type 2 diabetes mellitus	1.38e-05	5.17e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—HK1—type 2 diabetes mellitus	1.37e-05	5.16e-05	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.37e-05	5.15e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EDNRB—type 2 diabetes mellitus	1.37e-05	5.14e-05	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PTGS2—type 2 diabetes mellitus	1.37e-05	5.13e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	1.36e-05	5.11e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PSMD6—type 2 diabetes mellitus	1.36e-05	5.09e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HTR2C—type 2 diabetes mellitus	1.36e-05	5.09e-05	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.34e-05	5.05e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.34e-05	5.02e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—AGT—type 2 diabetes mellitus	1.34e-05	5.02e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	1.33e-05	5e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—HSD3B2—type 2 diabetes mellitus	1.33e-05	4.99e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—KCNJ11—type 2 diabetes mellitus	1.33e-05	4.99e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—LPA—type 2 diabetes mellitus	1.33e-05	4.99e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GCKR—type 2 diabetes mellitus	1.33e-05	4.99e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HTR2C—type 2 diabetes mellitus	1.33e-05	4.99e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PSMD6—type 2 diabetes mellitus	1.33e-05	4.99e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.32e-05	4.97e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EDNRA—type 2 diabetes mellitus	1.32e-05	4.96e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CALM1—type 2 diabetes mellitus	1.31e-05	4.94e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CYBA—type 2 diabetes mellitus	1.31e-05	4.93e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—AGT—type 2 diabetes mellitus	1.31e-05	4.91e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AVP—type 2 diabetes mellitus	1.31e-05	4.91e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.31e-05	4.91e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.3e-05	4.89e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.3e-05	4.86e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EDNRA—type 2 diabetes mellitus	1.29e-05	4.85e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	1.29e-05	4.85e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CALM1—type 2 diabetes mellitus	1.29e-05	4.83e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—GHRL—type 2 diabetes mellitus	1.29e-05	4.83e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PLAT—type 2 diabetes mellitus	1.29e-05	4.83e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CYBA—type 2 diabetes mellitus	1.29e-05	4.83e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.28e-05	4.81e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ALDOB—type 2 diabetes mellitus	1.27e-05	4.78e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.27e-05	4.77e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	1.26e-05	4.75e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—APOB—type 2 diabetes mellitus	1.26e-05	4.74e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PLAT—type 2 diabetes mellitus	1.26e-05	4.73e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—GHRL—type 2 diabetes mellitus	1.26e-05	4.73e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.26e-05	4.72e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.24e-05	4.67e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.24e-05	4.67e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.23e-05	4.64e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.21e-05	4.54e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—LPL—type 2 diabetes mellitus	1.21e-05	4.53e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.2e-05	4.49e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.19e-05	4.47e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GLP1R—type 2 diabetes mellitus	1.18e-05	4.45e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.18e-05	4.43e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—GCG—type 2 diabetes mellitus	1.18e-05	4.42e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.18e-05	4.42e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.17e-05	4.4e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.17e-05	4.38e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.16e-05	4.35e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.15e-05	4.33e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.15e-05	4.32e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—GCG—type 2 diabetes mellitus	1.15e-05	4.32e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.13e-05	4.25e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.13e-05	4.25e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.13e-05	4.24e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.11e-05	4.17e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SLC2A2—type 2 diabetes mellitus	1.1e-05	4.15e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.1e-05	4.13e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—C3—type 2 diabetes mellitus	1.09e-05	4.08e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CPT1A—type 2 diabetes mellitus	1.08e-05	4.07e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—MTR—type 2 diabetes mellitus	1.08e-05	4.07e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.08e-05	4.06e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.08e-05	4.06e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.08e-05	4.05e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NAMPT—type 2 diabetes mellitus	1.06e-05	3.99e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.06e-05	3.97e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.06e-05	3.97e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—HBA1—type 2 diabetes mellitus	1.05e-05	3.96e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—LIPC—type 2 diabetes mellitus	1.05e-05	3.96e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GCK—type 2 diabetes mellitus	1.05e-05	3.96e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP11A1—type 2 diabetes mellitus	1.05e-05	3.94e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.04e-05	3.89e-05	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IL6—type 2 diabetes mellitus	1.03e-05	3.88e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.03e-05	3.88e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AGT—type 2 diabetes mellitus	1.03e-05	3.87e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SLC9A1—type 2 diabetes mellitus	1.03e-05	3.87e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.02e-05	3.84e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CETP—type 2 diabetes mellitus	1.02e-05	3.82e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.01e-05	3.81e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.01e-05	3.81e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—APOE—type 2 diabetes mellitus	1.01e-05	3.8e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—LEP—type 2 diabetes mellitus	1.01e-05	3.8e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1e-05	3.76e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AVP—type 2 diabetes mellitus	1e-05	3.76e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MMP3—type 2 diabetes mellitus	1e-05	3.76e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—APOA1—type 2 diabetes mellitus	9.99e-06	3.75e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IGF2—type 2 diabetes mellitus	9.95e-06	3.74e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—GNB3—type 2 diabetes mellitus	9.92e-06	3.73e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	9.91e-06	3.72e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	9.81e-06	3.68e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AVP—type 2 diabetes mellitus	9.78e-06	3.68e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MMP3—type 2 diabetes mellitus	9.78e-06	3.68e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IGF2—type 2 diabetes mellitus	9.74e-06	3.66e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	9.7e-06	3.64e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—APOB—type 2 diabetes mellitus	9.66e-06	3.63e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IGF1R—type 2 diabetes mellitus	9.62e-06	3.61e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	9.6e-06	3.61e-05	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—AKT1—type 2 diabetes mellitus	9.53e-06	3.58e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PRKCB—type 2 diabetes mellitus	9.53e-06	3.58e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EDN1—type 2 diabetes mellitus	9.51e-06	3.57e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PSMD6—type 2 diabetes mellitus	9.46e-06	3.55e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SNAP25—type 2 diabetes mellitus	9.46e-06	3.55e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SREBF1—type 2 diabetes mellitus	9.46e-06	3.55e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—APOB—type 2 diabetes mellitus	9.46e-06	3.55e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	9.42e-06	3.54e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EDN1—type 2 diabetes mellitus	9.31e-06	3.5e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CTGF—type 2 diabetes mellitus	9.29e-06	3.49e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—LPL—type 2 diabetes mellitus	9.23e-06	3.47e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—HMGCR—type 2 diabetes mellitus	9.2e-06	3.46e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ADCY5—type 2 diabetes mellitus	9.03e-06	3.39e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—LPL—type 2 diabetes mellitus	9.03e-06	3.39e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IRS1—type 2 diabetes mellitus	9.02e-06	3.39e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ADRA2A—type 2 diabetes mellitus	9.01e-06	3.38e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	8.84e-06	3.32e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	8.66e-06	3.25e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP2E1—type 2 diabetes mellitus	8.65e-06	3.25e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—INS—type 2 diabetes mellitus	8.63e-06	3.24e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SLC2A1—type 2 diabetes mellitus	8.56e-06	3.21e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP1A2—type 2 diabetes mellitus	8.56e-06	3.21e-05	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—AKT1—type 2 diabetes mellitus	8.52e-06	3.2e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCR5—type 2 diabetes mellitus	8.5e-06	3.19e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCL2—type 2 diabetes mellitus	8.5e-06	3.19e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	8.47e-06	3.18e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IGF1—type 2 diabetes mellitus	8.35e-06	3.14e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AKT2—type 2 diabetes mellitus	8.35e-06	3.13e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP3A4—type 2 diabetes mellitus	8.34e-06	3.13e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCR5—type 2 diabetes mellitus	8.32e-06	3.13e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—EGFR—type 2 diabetes mellitus	8.31e-06	3.12e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—C3—type 2 diabetes mellitus	8.31e-06	3.12e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GCG—type 2 diabetes mellitus	8.2e-06	3.08e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SLC2A4—type 2 diabetes mellitus	8.2e-06	3.08e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—C3—type 2 diabetes mellitus	8.13e-06	3.05e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	7.93e-06	2.98e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	7.92e-06	2.98e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IRS2—type 2 diabetes mellitus	7.9e-06	2.97e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AGT—type 2 diabetes mellitus	7.89e-06	2.96e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.76e-06	2.92e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	7.75e-06	2.91e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IRS2—type 2 diabetes mellitus	7.73e-06	2.91e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—APOE—type 2 diabetes mellitus	7.73e-06	2.91e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—LEP—type 2 diabetes mellitus	7.73e-06	2.91e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AGT—type 2 diabetes mellitus	7.72e-06	2.9e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.65e-06	2.87e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.6e-06	2.85e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NOS3—type 2 diabetes mellitus	7.57e-06	2.84e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	7.57e-06	2.84e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—LEP—type 2 diabetes mellitus	7.57e-06	2.84e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—APOE—type 2 diabetes mellitus	7.57e-06	2.84e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.48e-06	2.81e-05	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—AKT1—type 2 diabetes mellitus	7.35e-06	2.76e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	7.29e-06	2.74e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	7.14e-06	2.68e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—RELA—type 2 diabetes mellitus	7.13e-06	2.68e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	7.07e-06	2.66e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	7.07e-06	2.66e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	7.04e-06	2.64e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	6.94e-06	2.61e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.9e-06	2.59e-05	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—AKT1—type 2 diabetes mellitus	6.87e-06	2.58e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.75e-06	2.54e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	6.74e-06	2.53e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—INS—type 2 diabetes mellitus	6.61e-06	2.48e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	6.56e-06	2.46e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.5e-06	2.44e-05	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	6.49e-06	2.44e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—INS—type 2 diabetes mellitus	6.47e-06	2.43e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	6.44e-06	2.42e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CASP3—type 2 diabetes mellitus	6.43e-06	2.41e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.39e-06	2.4e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL6—type 2 diabetes mellitus	6.39e-06	2.4e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.39e-06	2.4e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.36e-06	2.39e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.36e-06	2.39e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	6.3e-06	2.37e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	6.28e-06	2.36e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.25e-06	2.35e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.25e-06	2.35e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.22e-06	2.34e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	6.12e-06	2.3e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MMP9—type 2 diabetes mellitus	6.08e-06	2.28e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.07e-06	2.28e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	6.04e-06	2.27e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NFKB1—type 2 diabetes mellitus	6.01e-06	2.26e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.94e-06	2.23e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.89e-06	2.21e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	5.8e-06	2.18e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.79e-06	2.18e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.79e-06	2.18e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	5.69e-06	2.14e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.67e-06	2.13e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.67e-06	2.13e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SRC—type 2 diabetes mellitus	5.6e-06	2.1e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	5.51e-06	2.07e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.46e-06	2.05e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—RELA—type 2 diabetes mellitus	5.45e-06	2.05e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	5.41e-06	2.03e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	5.4e-06	2.03e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—RELA—type 2 diabetes mellitus	5.34e-06	2e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	5.33e-06	2e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.01e-06	1.88e-05	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.96e-06	1.86e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.92e-06	1.85e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.91e-06	1.84e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.89e-06	1.84e-05	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.86e-06	1.83e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.81e-06	1.81e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.78e-06	1.8e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	4.7e-06	1.77e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.65e-06	1.75e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	4.61e-06	1.73e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.6e-06	1.73e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.55e-06	1.71e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.51e-06	1.69e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.5e-06	1.69e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.41e-06	1.66e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SRC—type 2 diabetes mellitus	4.29e-06	1.61e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	4.23e-06	1.59e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SRC—type 2 diabetes mellitus	4.19e-06	1.58e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.17e-06	1.57e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.09e-06	1.53e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	4.04e-06	1.52e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	4.04e-06	1.52e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.83e-06	1.44e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL6—type 2 diabetes mellitus	3.77e-06	1.42e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.76e-06	1.41e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.75e-06	1.41e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	3.7e-06	1.39e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.68e-06	1.38e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.48e-06	1.31e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL6—type 2 diabetes mellitus	2.89e-06	1.08e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL6—type 2 diabetes mellitus	2.83e-06	1.06e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.66e-06	1e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.61e-06	9.79e-06	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	1.86e-06	6.98e-06	CbGpPWpGaD
